Pfizer’s revenue in Q2FY19 declined 9% yoy to Rs519.7cr. The decline in the revenue was on account of the high base in Q2FY18 due to re-stocking post-GST implementation. EBITDA declined 22.4% yoy to Rs129.8cr in Q2FY19 vs. Rs167.2cr in Q2FY18. EBITDA margins declined 431bps to 25% in Q2FY19 vs. 29.3% in Q2FY18 and 25.4% in Q1FY19. PAT declined 13.8% yoy to Rs95.8cr in Q2FY19 vs. Rs111.2cr in Q2FY18.
Gross margins improved 289bps yoy but declined 304bps qoq to 61% in Q2FY19.
Employee cost declined 1.6% yoy to Rs78cr in Q2FY19 vs. Rs79.3cr in Q2FY18.
Other expenses, however, grew 28.1% yoy to Rs109.1cr in Q2FY19 vs. Rs85.1cr in Q2FY18.
Total cash and bank balances stood at Rs404/share at the end of the H1FY19.
Pfizer Ltd is currently trading at Rs2,790.75, down 70.8 points, or 2.47%, from its previous close of Rs2,861.55 on the BSE. The scrip opened at Rs2,890 and has touched a high and low of Rs2,890 and Rs2,785.10, respectively. So far, 25,904 (NSE+BSE) shares were traded on the counter. The stock is currently trading above its 50-DMA.
Start investing in Equities, Derivatives, Mutual Funds and Currency
Temporary Password will be sent to your Mobile No. / Email Address to reset your password.
Make smart financial decisions
Trusted by more than 25 Lakhs Indians
Research and Stocks
Strategy and Tools
Terms & Conditions
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in National Do Not Call Registry as laid down by Telecom Regulatory Authority of India will not be applicable for such information/ communication.